Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intermediate dose Clear all
Completed Phase 3 Interventional Results available

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00929110
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 4, 2026, 5:40 AM EDT
Not listed Phase 2 Interventional

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

NCT01466205
View directory record Official record
Conditions
Cognitive Impairments, Schizotypal Personality Disorder
Interventions
DAR-0100A, Placebo
Drug
Lead sponsor
Larry J. Siever
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Vitamin D Status on Bones in Breastfed Infants

NCT00697294
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Tri-Vi-Sol
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 2 Hours
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2011 · Synced Sep 4, 2026, 5:40 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

NCT05538624
View directory record Official record
Conditions
Neoplasm, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenocarcinoma Ovary, Serous Adenocarcinoma of Ovary, Serous Adenocarcinoma of Primary Peritoneum, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma
Interventions
AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase)
Drug
Lead sponsor
Avenge Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Bethesda, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

NCT03357796
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Sep 4, 2026, 5:40 AM EDT
Recruiting Phase 3 Interventional

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

NCT06911424
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Fusidic Acid 1%, Placebo
Drug
Lead sponsor
Baxis Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
38
States / cities
Little Rock, Arkansas • Huntington Beach, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 4, 2026, 5:40 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

NCT02923180
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enoblituzumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Phase 3 Interventional

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

NCT00078988
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
filgrastim, carboplatin, etoposide, isotretinoin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00624286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
118
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

NCT01397708
View directory record Official record
Conditions
Melanoma
Interventions
INXN-2001, INXN-1001
Biological · Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Park Ridge, Illinois • Goshen, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 4, 2026, 5:40 AM EDT
Active, not recruiting Not applicable Interventional

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

NCT03621644
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Radiation
Lead sponsor
Viewray Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 4, 2026, 5:40 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

NCT07348237
View directory record Official record
Conditions
Chronic Kidney Failure, End-Stage Renal Disease, Renal Impairment
Interventions
MK-2828
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
24 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 4, 2026, 5:40 AM EDT
Recruiting Phase 4 Interventional

AWARE: Management of ADHD in Autism Spectrum Disorder

NCT05916339
View directory record Official record
Conditions
ADHD, Autism Spectrum Disorder
Interventions
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Drug
Lead sponsor
Daniel Coury
Other
Eligibility
4 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • Portland, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

NCT00071799
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Azacitidine, Physician Choice
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 4, 2026, 5:40 AM EDT
Active, not recruiting Phase 2 Interventional

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

NCT03323463
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck
Interventions
F-FMISO PET/CT Scan, 30 Gy over 3 weeks, Cisplatin, Carboplatin, 5Fluorouracil, Proton Therapy
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

NCT02096263
View directory record Official record
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing the Dose-response of Coordination Training for Older Adults.

NCT03629730
View directory record Official record
Conditions
Mobility Limitation
Interventions
Coordination training
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
70 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 4, 2026, 5:40 AM EDT
Withdrawn Phase 4 Interventional

Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy

NCT03613792
View directory record Official record
Conditions
Bronchoscopy
Interventions
Remifentanil, Fentanyl, Midazolam, Ketamine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 4, 2026, 5:40 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

NCT03598309
View directory record Official record
Conditions
Lung Diseases, Lung Cancer, Protection Against
Interventions
Curcumin C3 complex®, Lovaza®, Placebo
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 4, 2026, 5:40 AM EDT
Terminated Phase 1 Interventional

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

NCT04465487
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
REGN6569, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 4, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

NCT00023244
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 20 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers

NCT04484532
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
40 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 4, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

NCT02160145
View directory record Official record
Conditions
Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan (OPC-41061), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 4, 2026, 5:40 AM EDT
Terminated Phase 4 Interventional Results available

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

NCT04567225
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 4, 2026, 5:40 AM EDT